Sam Fazeli

speaker

906 appearances 5 recordings 1 series first heard Oct 2025 last heard 31 Mar

Sam Fazeli’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 5 in all, peaking in Mar 2026 with 2.

Appearances

newest first · ▶ plays the moment

Vanguards of Healthcare by Bloomberg Intelligence · Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates · 27 Oct 2025 podcast

Okay, now just back to, we'll come to Destiny Breast05 in a minute, but in DB11, you did say, and I think you explained very clearly at the analyst meeting that I think is freely available on your website for folks to listen to if they needed to, that although the comparator arm was a standard of care,

It's not the only standard of care.

And I think the explanation was also given that, don't forget, this trial was started even before COVID, right?

And then you ended up in a situation where you, you know, so over time, of course, when you do these long trials, there is a potential for change in standard of care.

How would we read that in terms of how sure are you if physicians wanted to use this with another standard

combo, that they would get similar results?

Or do you think there would have to be done, further trials have to be done?

Okay, and then one last question on DB11 before we move on to DB05, and that is the ILD pneumonitis rates.

ILD is one of the side effects of N HER2 and other HER2-targeting ADCs and even some other ADCs, I think.

So, but you represented them as a combination.

Now, ILD is a, if I'm not wrong, and you can correct me if I am wrong, is a relatively, has a risk of long-term consequences, whereas pneumonitis is maybe viewed as a more short-term issue.

Was there much of a difference between the two?

I mean, if you had X percent, what was most of it pneumonitis versus ILD?

How should we think about that?

And what would it mean for this patient population that is expected to live a long time?

So DDO5, which was the trial that you've referred to already, was an adjuvant trial, i.e.

patients were getting whatever neoadjuvant therapy the physician was giving them or none.

I'm assuming they all had some kind of neoadjuvant therapy, but you can, again, detail on that.

And then they got their surgery and then post-surgery,

If they had residual disease, i.e.

Showing 741–760 of 906 · page 38 of 46